The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.

Claims

32 · 1 independent · depth 3

32 granted claims

›1.independentA method for treating a cancer comprising administering a therapeutically effective amount of a compound selected from the group consisting of+31

›2.↳ 1The method of claim 1, further comprising administering an antiandrogen to the subject.d2+13

›3.↳ 2The method of claim 2, wherein the composition is administered at a dosage of the compound in a range selected from the group consisting of from about…d3

›4.↳ 2The method of claim 2, wherein the composition is administered at a dosage of the compound of about 1 mg per kg body weight per day.d3

›5.↳ 2The method of claim 2, wherein the compound is administered by intravenous injection, by injection into tissue, intraperitoneally, orally, or nasally.d3

›6.↳ 2The method of claim 2, wherein the compound is in a form selected from the group consisting of a solution, dispersion, suspension, powder, capsule, ta…d3

›10.↳ 2The method of claim 2, wherein the compound isd3

›11.↳ 2The method of claim 2, wherein the antiandrogen is selected from the group consisting of a non-steroidal antiandrogen and bicalutamide.d3

›12.↳ 2The method of claim 2, wherein the cancer is selected from the group consisting of prostate cancer, hormone sensitive prostate cancer, and hormone ref…d3

›13.↳ 2The method of claim 2,nwherein the cancer is prostate cancer andwherein administering the compound prevents the prostate cancer from progressing to ho…d3

›14.↳ 2The method of claim 2,nwherein the cancer is hormone sensitive prostate cancer andwherein administering the compound prevents the hormone sensitive pr…d3

›15.↳ 2The method of claim 2, wherein the cancer is selected from the group consisting of breast cancer, hormone sensitive breast cancer, and hormone refract…d3

›16.↳ 2The method of claim 2,nwherein the cancer is breast cancer andwherein administering the compound prevents the breast cancer from progressing to hormon…d3

›17.↳ 2The method of claim 2,nwherein the cancer is hormone sensitive breast cancer andwherein administering the compound prevents the hormone sensitive brea…d3

›18.↳ 2The method of claim 2, wherein the cancer is selected from the group consisting of ovarian cancer, hormone sensitive ovarian cancer, and hormone refra…d3

›7.↳ 1The method of claim 1, wherein the compound isd2

›8.↳ 1The method of claim 1, wherein the compound isd2

›9.↳ 1The method of claim 1, wherein the compound isd2

›19.↳ 1The method of claim 1,nfurther comprising administering an antiandrogen to the subject,wherein the compound is administered after administering the an…d2+3

›23.↳ 1The method of claim 1, further comprising administering an antiestrogen to the subject.d2+5

›29.↳ 1The method of claim 1,nfurther comprising administering an antiestrogen to the subject,wherein the compound is administered after administering the an…d2+2

›32.↳ 1The method of claim 1, further comprising administering a receptor modulator selected from the group consisting of an estrogen receptor modulator and …d2

Classifications

6 codes

IPC · International Patent Classification

Section A — Human necessities

A61K31/4184
A61K31/4166

Section C — Chemistry; metallurgy

C07D233/86

USPC · US Patent Classification

514/391548/321.1548/301.4

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoom

USPTOApplicanthover for detail · click to open

Pendency

1.9 y

679 days filing → grant

Office actions

non-final + final

Responses

5 RCE

Interviews

examiner interview summaries

Examiner

Michael Barker

art unit 1626 · TC 1600

Law firm

Law firm · Log in to unlock

Citations: 394 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Priority chain

2 priority documents

Priority

29 Mar 2006

earliest claimed

›Priority documents — 2

Type	Document	Date
provisional	US 60786837	29 Mar 2006
related publication	US 20120295944 A1	22 Nov 2012

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.